Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
17 employees
Upstream Bio: Clinical-stage developer of monoclonal antibody therapy for severe asthma.
HQ
Founded
2021
Upstream Bio, founded with the mission to conquer inflammation at its source, is a clinical-stage company specializing in the development of monoclonal antibody therapies. The company's primary focus is on severe asthma, targeting the TSLP receptor to inhibit various immune signaling cascades. By addressing this validated target, Upstream Bio aims to alleviate the burden of inflammatory and allergic diseases on patients and their families.
Notable figures affiliated with Upstream Bio include industry veterans with substantial experience in biopharmaceuticals. The company has garnered attention from key investors in the healthcare sector, reflecting confidence in its innovative approach. Among its achievements, Upstream Bio has advanced its lead antibody therapy into clinical trials, marking significant progress in its mission to provide effective treatments for severe asthma and related conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Antibody Therapy
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Upstream Bio founded?
Upstream Bio was founded in 2021.
Where is Upstream Bio's headquarters located?
Upstream Bio's headquarters is located in Waltham, MA, US.
When was Upstream Bio's last funding round?
Upstream Bio's most recent funding round was for $200M (USD) in June 2023.
How many employees does Upstream Bio have?
Upstream Bio has 17 employees as of Feb 4, 2024.
How much has Upstream Bio raised to-date?
As of July 05, 2023, Upstream Bio has raised a total of $408M (USD) since Jun 8, 2023.
Add Comparison
Total Raised to Date
$408M
USD
Last Update Jun 8, 2023
Last Deal Details
$200M
USD
Jun 8, 2023
Series B
Current Employees
17
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts